Par Pharmaceutical Companies Reaches New 52-Week High (PRX)

NEW YORK ( TheStreet) -- Par Pharmaceutical Companies (NYSE: PRX) hit a new 52-week high Friday as it is currently trading at $39.19, above its previous 52-week high of $39.12 with 11,544 shares traded as of 9:45 a.m. ET. Average volume has been 412,700 shares over the past 30 days.

Par Pharmaceutical Companies has a market cap of $1.31 billion and is part of the health care sector and drugs industry. Shares are up 18.7% year to date as of the close of trading on Thursday.

Par Pharmaceutical Companies, Inc., together with its subsidiaries, engages in developing, licensing, manufacturing, marketing, and distributing generic and branded products primarily in the United States.

TheStreet Ratings rates Par Pharmaceutical Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Par Pharmaceutical Companies Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing